Head and Neck Cancer: An Overview

ABSTRACT

Ablative surgery for malignancies of the upper aerodigestive tract is the most common reason why the reconstructive surgeon is called upon to reconstruct adult head and neck defects. An understanding of the pathophysiology and treatment of head and neck malignancy is vital to the reconstructive surgeon so that restoration of both form and function can be achieved. It is important to understand the behavior of cancers of each head and neck subsite, as staging and ultimately the treatment of tumors from each subsite is different. Historically, the standard treatment of head and neck cancer was surgery and/or primary radiation therapy with surgical salvage for failure. Beginning in the 1980s, advances in chemotherapy and concurrent delivery with radiation offered new options to standard surgical therapy. Over the past two decades, the concept of organ preservation using chemotherapy together with radiation therapy has been definitively established. Yet, even with the strides made over these two decades with chemoradiation, surgical treatment of head and neck cancer and reconstruction thereof will be an important treatment option for the foreseeable future. Therefore, the relationship between the extirpative and reconstructive surgeon is vital, and a clear understanding of the biology and behavior of head and neck malignancy is crucial to successful patient outcomes.

KEYWORDS

Head - neck - cancer

REFERENCES

• 1 Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression.  Cancer Res. 2006;  66 5527-5536
• 2 Haerle S K, Strobel K, Hany T F, Sidler D, Stoeckli S J. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma.  Head Neck 2009. 2010;  32 319-325
• 3 Garavello W, Ciardo A, Spreafico R, Gaini R M. Risk factors for distant metastases in head and neck squamous cell carcinoma.  Arch Otolaryngol Head Neck Surg. 2006;  132 762-766
• 4 Herrero R, Castellsagué X, Pawlita M IARC Multicenter Oral Cancer Study Group et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.  J Natl Cancer Inst. 2003;  95 1772-1783
• 5 Hicks Jr W L, Loree T R, Garcia R I et al.. Squamous cell carcinoma of the floor of mouth: a 20-year review.  Head Neck. 1997;  19 400-405
• 6 Lin D T, Cohen S M, Coppit G L, Burkey B B. Squamous cell carcinoma of the oropharynx and hypopharynx.  Otolaryngol Clin North Am. 2005;  38 59-74 viii
• 7 Mendenhall W M, Morris C G, Amdur R J, Hinerman R W, Werning J W, Villaret D B. Definitive radiotherapy for squamous cell carcinoma of the base of tongue.  Am J Clin Oncol. 2006;  29 32-39
• 8 Shaha A R, Shah J P. Carcinoma of the subglottic larynx.  Am J Surg. 1982;  144 456-458
• 9 The Department of Veterans Affairs Laryngeal Cancer Study Group . Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.  N Engl J Med. 1991;  324 1685-1690
• 10 Lefebvre J L, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. EORTC Head and Neck Cancer Cooperative Group . Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial.  J Natl Cancer Inst. 1996;  88 890-899
• 11 Harari P M, Harris J, Kies M S et al.. Phase II randomized trial of surgery followed by chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234).  Int J Radiat Oncol Biol Phys. 2007;  69(3 Suppl) S13